相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer The Randomized Clinical FinXX Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2017)
IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells
Yacine Merrouche et al.
ONCOTARGET (2016)
MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors
Masayuki Hiraki et al.
SCIENTIFIC REPORTS (2016)
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells
Sarah Mombelli et al.
SCIENTIFIC REPORTS (2015)
Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers
Sylvain Lefort et al.
AUTOPHAGY (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells
Yasumitsu Uchida et al.
CANCER BIOLOGY & THERAPY (2013)
Activated EGFR Stimulates MUC1 Expression in Human Uterine and Pancreatic Cancer Cell Lines
Neeraja Dharmaraj et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
D. W. Kufe
ONCOGENE (2013)
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
X. Sui et al.
CELL DEATH & DISEASE (2013)
IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2
Stephanie Cochaud et al.
SCIENTIFIC REPORTS (2013)
EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin αvβ5 Depends on Activation of c-Src and Cleavage of MUC1
Steven K. M. Lau et al.
PLOS ONE (2012)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2011)
MUC1 regulates nuclear localization and function of the epidermal growth factor receptor
Benjamin G. Bitler et al.
JOURNAL OF CELL SCIENCE (2010)
Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells
S. Bafna et al.
ONCOGENE (2010)
Regulation Mechanisms and Signaling Pathways of Autophagy
Congcong He et al.
ANNUAL REVIEW OF GENETICS (2009)
MUC1 oncoprotein is a druggable target in human prostate cancer cells
Maya Datt Joshi et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-α-induced cell death in MCF-7 cells
U. Sivaprasad et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
MUC1/X protein immunization enhances cDNA immunization in generating Anti-MUC1 α/β junction antibodies that target malignant cells
Daniel B. Rubinstein et al.
CANCER RESEARCH (2006)
The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts
D Raina et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
